Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Mature
Primary summary from verified readiness
- Confidence
- 65% · fresh
- Computed at
- 2026-08-20T10:56:11.727269+00:00
- Claimed
- 100
- Reported
- 97
- Verified
- 90
- Gap
- +10
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Proceed with caution
- Why
- First systemically active engineered oncolytic-virus immunotherapy to win FDA approval in combination with a checkpoint inhibitor — a genuine first-in-class regulatory and mechanistic milestone now commercially available — but the approval itself rests on an accelerated pathway that FDA's own reviewers twice rejected as evidentiarily uninterpretable (single-arm design, unconfirmable individual drug contribution), overturned only via a contested 10-3 advisory-committee vote amid public/political pressure. Real and live, but durability of benefit is not yet independently proven.
- Next
- Track the IGNYTE-3 confirmatory Phase 3 OS readout (~2030), post-launch real-world response/safety data, and whether this becomes a repeatable oncolytic-virus regulatory template; revisit the register entry at next material update.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 0
- Tier 2
- 3
- Tier 3
- 2
- Supports
- 3
- Contradicts
- 1
- Context
- 1
- Latest observed
- 2026-08-06
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-17 Reading moved from mature to mature.